Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-03-21
1999-08-17
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514252, 514256, 514340, 514379, 544238, 544333, 5462721, 548241, 548246, A61K 3142, A61K 31505, C07D26114, C07D23924
Patent
active
059394463
ABSTRACT:
Compounds of the formula ##STR1## inhibit the activity of endothelin.
REFERENCES:
patent: 2888455 (1959-05-01), Kano et al.
patent: 4415496 (1983-11-01), Harris et al.
patent: 4661479 (1987-04-01), Wyvratt, Jr. et al.
patent: 5236928 (1993-08-01), Chakravarty et al.
patent: 5270313 (1993-12-01), Burri et al.
patent: 5292740 (1994-03-01), Burri et al.
patent: 5378715 (1995-01-01), Stein et al.
patent: 5464853 (1995-11-01), Chan et al.
patent: 5514691 (1996-05-01), Chan et al.
patent: 5514696 (1996-05-01), Murugesan et al.
patent: 5571821 (1996-11-01), Chan et al.
patent: 5591761 (1997-01-01), Chan et al.
patent: 5594021 (1997-01-01), Chan et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5760038 (1998-06-01), Murugesan et al.
patent: 5780473 (1998-07-01), Murugesan et al.
S. Norio et al., Chemical Abstracts, vol. 70, No. 19, (1969), 87639g.
T. Saito, Chemical Abstracts, vol. 73, No. 23 (1970), 120511w.
Derwent Abstract No. 88-289069/41 Feb. 27, 1987.
Derwent Abstract No. 88-195835/28 Nov. 26, 1986.
Derwent Abstract No. 88-061295/09 Jul. 9, 1986.
Derwent Abstract No. 87-152485/22 Oct. 11, 1985.
Derwent Abstract No. 62299 E/30 Dec. 11, 1980.
Derwent Abstract No. 40927 D/23 Sep. 11, 1979.
Derwent Abstract No. 91-254550/35 Feb. 19, 1990.
Derwent Abstract No. 86-246709/38 Nov. 27, 1985.
Derwent Abstract No. 35012 K/15 Sep. 24, 1981.
Allen et al., "Preparation . . . antagonists", CA116(11):106284Z, p. 778, 1992.
R.D. Desai et al., Chemical Abstracts, vol. 71, No. 11, (1969) 49825c.
R.D. Desai et al., Chemical Abstracts, vol. 71, No. 3, (1969) 12872q.
P. G. Ferrini et al., Angew. Chem. Internat. Edit., vol. 2, No. 2 (1963) p. 99.
A. M. van Leusen, et al., "Synthesis . . . Compounds", J. Org. Chem., vol. 41, No. 4, (1976), pp. 69-71.
W. J. Hammar et al., J. Heterocyclic Chem., vol. 18, (1981) pp. 885-888.
A. M. van Leusen et al., Tetrahedron Letters, No. 23, (1972), pp. 2369-2372.
Chan et al., "Identification of a New Class of ET.sub.A Selective Endothelin Antagonists by Pharmacophore Directed Screening", Biochemical and Biophysical Research Communications, vol. 201, No. 1, May 30, 1994, pp. 228-234.
Stein et al., "The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ET.sub.A Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide", J. Med. Chem., vol. 37, No. 3, Feb. 4, 194, pp. 329-331.
Doherty, J. Med. Chem., 35(9), 1493-1508 (May 1992).
CA 65: 2241d (1966).
CA 92:41908v (1979).
Wang et al., "Nitrile . . . sinomin," CA 108:94444w, p. 651 (1988).
Khanna, "Oral . . . formulation," CA 115:35728p, p. 415 (1991).
Stein et al., "The Discovery . . . 1-naphthalenesulfonamide," CA 120:18233n, pp. 21-22 (1994).
Vree et al., "Renal excretion . . . function," CA 97:84685r, p. 23 (1982).
Oie, "Pharmacokinetics . . . dosing," CA 102:197512x, p. 18 (1985).
Murugesan et al., "N-(heteroaryl) . . . antagonists," CA 120:270370c, p. 1067 (1994).
Chan et al., Am. J. Physiol., "Effect of an endothelin-receptor antagonist on ischemic acute renal failure", 1994, vol. 266, pp. F135-F138.
Marsen et al., "Renal actions of endothelin . . . " Kidney Int., 1994, vol. 45, pp. 336-344.
Mitaka et al., "Endothelin-1 and atrial natriuretic peptide in septic shock", Am. Heart J., 1993, vol. 126, pp. 466-468.
Hirata et al., "Plasma Endothelins in Sepsis Syndrome", JAMA, 1993, vol. 270, p. 2182.
Battistini et al., "Growth Regulatory Properties of Endothelins", Peptides, 1993, vol. 14, pp. 385-399.
Ohlstein et al., "The selective endothelin ET.sub.A . . . ", Eur. J. Pharmcol., 1992, vol. 225, pp. 347-350.
Winkles et al., "Endothelin-1 and Endothelin Receptor . . . ", Biochem. Biophys. Res. Comm., 1993, vol. 191, pp. 1081-1088.
Kowala, "Endothelin receptors and atherosclerosis . . .", Exp. Opin. Invest. Drugs, 1996, vol. 5, pp. 1495-1508.
Kowala et al., "Selective Blockade of the Endothelin Subtype A . . . ", Am. J. Pathol., 1995, vol. 146, pp. 819-826.
Lerman et al., "Circulating And Tissue Endothelin . . . ", 1991, vol. 325, pp. 997-1001.
Douglas et al., "A Role for Endogenous Endothelin-1 . . . ", Circ. Res., 1994, vol. 75, pp. 190-197.
Tahara et al., "Ciculating Immunoreactive Endothelin . . . ", Metabolism, 1991, vol. 40, pp. 1235-1237.
Kobayashi et al., "Localization Of Endothelin Receptors In The Human Prostrate", J. Urol., 1991, vol. 151, pp. 763-766.
Kobayashi et al, "Binding and Functional Properties of Endothelin . . . " Mol. Pharmcol., 1994, vol. 45, pp. 306-311.
Kiowski et al., "Evidence of Endothelin-1 mediated vasoconstriction . . . ", Lancet, 195, vol. 346, pp. 732-736.
Sakai et al., "Inhibition of myocardial endothelin pathway . . . ", Nature, 1996, vol. 384, pp. 353-355.
Bradbury et al., New Non-Peptide Edothelin-A Receptor Antagonists: Synthesis, Biological Properties, and Structure-Activity Relationships of 5-(Dimethylamino)-N-Pyridyl, -N-Pyrimidinyl-, -N-Pyridazinyl-, and -N-Pyrazinyl-1-Naphthalenesulfonamides, Journa, Mar. 1997.
Stein et al., Discovery and Structure-Activity Relationships of Sulfonamide ETA-Selective Antagonists, Journal of Medicinal Chemistry, vol. 38, pp. 1344-1354, 1995.
Barrish Joel C.
Murugesan Natesan
Babajko Suzanne E.
Bristol-Myers Squibb Co.
Coleman Brenda
Davis Stephen B.
Raymond Richard L.
LandOfFree
Heteroaryl substituted phenyl isoxazole sulfonamide endothelin a does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl substituted phenyl isoxazole sulfonamide endothelin a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl substituted phenyl isoxazole sulfonamide endothelin a will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-315125